The FDA is slated to announce its decision on glaucoma candidate Vesneo on August 24, 2017.Vesneo is licensed by Nicox to Valeant Pharmaceuticals International Inc.'s (VRX) (VRX.TO) subsidiary, Bausch + Lomb.The Company is seeking approval of Vesneo, an intraocular pressure (IOP) lowering single-agent eye drop dosed once daily, for patients with open angle glaucoma (OAG) or ocular hypertension (OHT).Open-angle glaucoma, which is the most common form of glaucoma, is caused by the slow clogging of trabecular meshwork - the drainage canal of the eye, resulting in increased eye pressure, and is characterized by a wide and open angle between the iris and cornea.The peak sales potential of Vesneo is estimated to be over $500 million in the U.S. alone and roughly in excess of $1 billion globally.VRX closed Friday's (July 28) trading at $16.84, down 1.69%.